Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,157 shares of the medical research company's stock after selling 3,020 shares during the period. Kintegral Advisory LLC's holdings in Thermo Fisher Scientific were worth $3,066,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $25,000. Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Cassady Schiller Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after purchasing an additional 33 shares during the last quarter. Finally, VSM Wealth Advisory LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Royal Bank Of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, Stifel Nicolaus decreased their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $604.05.

Thermo Fisher Scientific Price Performance

TMO stock traded up $0.49 during midday trading on Friday, hitting $428.25. 1,359,321 shares of the stock were exchanged, compared to its average volume of 1,974,470. The stock's 50-day moving average price is $409.18 and its 200-day moving average price is $479.65. The stock has a market cap of $161.66 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 2.28 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.11 earnings per share. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.